Executive summary of Chinese expert consensus for topical application of anti-microbial agents for lower respiratory tract infection in adults

查看全文 作　　者：Jing [1]Zhang;Qijian [2]Cheng;Yi [3]Huang;Hong [4]Fan;Guoxiang [5]Lai;Xiangdong [6]Mu;Wei [7]Sha;Danyang [8]She;Ning [9]Shen;Xin [10]Su;Jinfu [11]Xu;Feng [12]Ye;Xinlun [13]Tian;Tiantuo [14]Zhang;Hua [15]Zhou;Youning [16]Liu;Lixian [1]He;Heping [7]Xiao;Bei [9]He;Yi [10]Shi;Xiangyan [17]Zhang;Bin [18]Cao;Jieming [2]Qu;on behalf of Pulmonary Infection Assembly of Chinese Thoracic [19]Society 机构地区：[1]Department of Pulmonary and Critical Care Medicine,Zhongshan Hospital,Shanghai Medical College,Fudan University,Shanghai 200032,China;[2]Department of Pulmonary and Critical Care Medicine,Ruijin Hospital,Institute of Respiratory Diseases,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;[3]Department of Pulmonary and Critical Care Medicine,Shanghai Changhai hospital,Navy Medical University,Shanghai 200433,China;[4]Department of Pulmonary and Critical Care Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;[5]Department of Respiratory and Critical Care Medicine,The Second Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou,Fujian 350003,China;[6]Department of Respiratory and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,Beijing 102218,China;[7]Department of Pulmonary Tuberculosis,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China;[8]Department of Pulmonary and Critical Care Medicine,The First Medical Center of the General Hospital of Chinese People's Liberation Army,Beijing 100853,China;[9]Department of Respiratory Medicine,Peking University Third Hospital,Beijing 100191,China;[10]Department of Pulmonary and Critical Care Medicine,Nanjing Jinling Hospital,School of Medicine,Nanjing University,Nanjing,Jiangsu 210002,China;[11]Department of Respiratory and Critical Care Medicine,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China;[12]State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Medical University,Guangzhou,Guangdong 510120,China;[13]Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Beijing 100032,China;[14]Department of Pulmonary and Critical Care Medicine,The Third Affiliated Hospital,Sun Yat-Sen University,Guangzhou,Guangdong 510630,China;[15]Department of Pulmonary Medicine,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310009,China;[16]Department of Pulmonary and Critical Care Medicine,The General Hospital of Chinese People's Liberation Army,Beijing 100853,China;[17]Department of Pulmonary and Critical Care Medicine,Guizhou Provincial People's Hospital,Guiyang,Guizhou 550002,China;[18]Department of Pulmonary and Critical Care Medicine,China-Japan Friendship Hospital,Capital Medical University,Beijing 100029,China;[19]不详 出　　处：《Chinese Medical Journal》索引2022年第135卷第22期,共3页 摘　　要：In recent years,with the increased prevalence of multi-drug resistant(MDR)bacterial infection and chronic pulmonary infection,the topical application of anti-microbial agents,mainly inhaled antibiotics,has come back to clinical practice.Several formulations for nebulization and dry powder inhaler(DPI)have been approved for inhaled anti-infective therapy.Meanwhile,evidence and experience have been accumulated in the use of anti-microbial agents delivered via airway.However,the available studies in this field are heterogenous in the study population,drug delivery route and dosages.The efficacy and safety of inhaled anti-infective therapy in various types of lower respiratory tract infections(LRTIs)need to be evaluated.Moreover. 关 键 词：infection DOSAGE application